For management of HAE-nC1INH attacks, treatment with a plasma-derived C1INH concentrate, bradykinin B2 receptor antagonist (icatibant), or plasma kallikrein inhibitor (ecallantide) is generally effective. Here, KLK4 is linked to hereditary angioedema.